MA29288B1 - Agonistes et antagonistes complets et partiels tres puissants du recepteur de la nociceptine/orphanine fq - Google Patents
Agonistes et antagonistes complets et partiels tres puissants du recepteur de la nociceptine/orphanine fqInfo
- Publication number
- MA29288B1 MA29288B1 MA30190A MA30190A MA29288B1 MA 29288 B1 MA29288 B1 MA 29288B1 MA 30190 A MA30190 A MA 30190A MA 30190 A MA30190 A MA 30190A MA 29288 B1 MA29288 B1 MA 29288B1
- Authority
- MA
- Morocco
- Prior art keywords
- orphanine
- nociceptin
- antagonists
- receptor
- partial agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
L'INVENTION CONCERNE DES ANALOGUES DE PEPTIDES DE LA NOCICÉPTINE/ORPHANINE FQ, DES COMPOSITIONS DE CEUX-CI ET L'UTILISATION DE CEUX-CI DANS LE TRAITEMENT DE TROUBLES ET DE DYSFONCTIONNEMENTS RELATIFS À L'ACTIVATION OU AU BLOCAGE DES RÉCEPTEURS NOP.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000003A ITFE20050003A1 (it) | 2005-02-15 | 2005-02-15 | Agonisti pieni e parziali ed antagonisti del recettore per nocicettina/orfanina fq ad elevata potenza. |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29288B1 true MA29288B1 (fr) | 2008-02-01 |
Family
ID=36685750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30190A MA29288B1 (fr) | 2005-02-15 | 2007-08-31 | Agonistes et antagonistes complets et partiels tres puissants du recepteur de la nociceptine/orphanine fq |
Country Status (29)
Country | Link |
---|---|
US (1) | US8227414B2 (fr) |
EP (1) | EP1851241B1 (fr) |
JP (1) | JP5281292B2 (fr) |
KR (1) | KR101294895B1 (fr) |
CN (2) | CN101128482A (fr) |
AU (1) | AU2006215639B2 (fr) |
BR (1) | BRPI0606998B8 (fr) |
CA (1) | CA2598121C (fr) |
CR (1) | CR9379A (fr) |
CU (1) | CU23823A3 (fr) |
CY (1) | CY1116456T1 (fr) |
DK (1) | DK1851241T3 (fr) |
EA (1) | EA011325B1 (fr) |
ES (1) | ES2541308T3 (fr) |
HR (1) | HRP20150731T1 (fr) |
HU (1) | HUE025000T2 (fr) |
IL (1) | IL185235A (fr) |
IT (1) | ITFE20050003A1 (fr) |
MA (1) | MA29288B1 (fr) |
MX (1) | MX2007009523A (fr) |
NI (1) | NI200700205A (fr) |
NO (1) | NO341856B1 (fr) |
PL (1) | PL1851241T3 (fr) |
PT (1) | PT1851241E (fr) |
RS (1) | RS54095B1 (fr) |
SI (1) | SI1851241T1 (fr) |
UA (1) | UA91844C2 (fr) |
WO (1) | WO2006087340A2 (fr) |
ZA (1) | ZA200707714B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITNA20090026A1 (it) * | 2009-05-14 | 2010-11-15 | Agostino Bruno D | Agonisti del recettore nop e loro usi terapeutici |
CN112730849B (zh) * | 2021-01-14 | 2023-03-10 | 山西医科大学第二医院 | 内源性孤啡肽作为糖尿病合并无症状性心肌缺血的血清生物标志物的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1499888T1 (sl) | 2002-04-29 | 2010-11-30 | Euro Celtique Sa | Konformacijsko omejeni peptidi ki vežejo ORL receptor |
ITMI20022022A1 (it) | 2002-09-24 | 2004-03-25 | Girolamo Calo' | Analoghi di nocicettina. |
ITMI20031349A1 (it) | 2003-07-01 | 2005-01-02 | Ufpeptides S R L | Antagonisti del recettore nop e loro usi terapeutici. |
CN1634980A (zh) * | 2004-10-10 | 2005-07-06 | 兰州大学 | 孤啡肽的类似物 |
-
2005
- 2005-02-15 IT IT000003A patent/ITFE20050003A1/it unknown
-
2006
- 2006-02-15 SI SI200631947T patent/SI1851241T1/sl unknown
- 2006-02-15 PT PT67082859T patent/PT1851241E/pt unknown
- 2006-02-15 US US11/884,241 patent/US8227414B2/en not_active Expired - Fee Related
- 2006-02-15 DK DK06708285.9T patent/DK1851241T3/en active
- 2006-02-15 MX MX2007009523A patent/MX2007009523A/es active IP Right Grant
- 2006-02-15 BR BRPI0606998A patent/BRPI0606998B8/pt not_active IP Right Cessation
- 2006-02-15 ES ES06708285.9T patent/ES2541308T3/es active Active
- 2006-02-15 KR KR1020077018487A patent/KR101294895B1/ko active IP Right Grant
- 2006-02-15 EA EA200701732A patent/EA011325B1/ru not_active IP Right Cessation
- 2006-02-15 CA CA2598121A patent/CA2598121C/fr not_active Expired - Fee Related
- 2006-02-15 CN CNA2006800049929A patent/CN101128482A/zh active Pending
- 2006-02-15 PL PL06708285T patent/PL1851241T3/pl unknown
- 2006-02-15 CN CN201510080020.9A patent/CN104689293A/zh active Pending
- 2006-02-15 UA UAA200709286A patent/UA91844C2/ru unknown
- 2006-02-15 RS RS20150443A patent/RS54095B1/en unknown
- 2006-02-15 AU AU2006215639A patent/AU2006215639B2/en not_active Ceased
- 2006-02-15 WO PCT/EP2006/050958 patent/WO2006087340A2/fr active Application Filing
- 2006-02-15 EP EP06708285.9A patent/EP1851241B1/fr active Active
- 2006-02-15 HU HUE06708285A patent/HUE025000T2/en unknown
- 2006-02-15 JP JP2007554583A patent/JP5281292B2/ja not_active Expired - Fee Related
-
2007
- 2007-08-09 NI NI200700205A patent/NI200700205A/es unknown
- 2007-08-13 CU CU20070195A patent/CU23823A3/es active IP Right Grant
- 2007-08-13 IL IL185235A patent/IL185235A/en active IP Right Grant
- 2007-08-31 MA MA30190A patent/MA29288B1/fr unknown
- 2007-09-07 ZA ZA200707714A patent/ZA200707714B/xx unknown
- 2007-09-13 CR CR9379A patent/CR9379A/es not_active Application Discontinuation
- 2007-09-14 NO NO20074702A patent/NO341856B1/no not_active IP Right Cessation
-
2015
- 2015-07-06 HR HRP20150731TT patent/HRP20150731T1/hr unknown
- 2015-07-06 CY CY20151100579T patent/CY1116456T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR24C1011I1 (fr) | Diaminopyrimidines utilisees en tant qu'antagonistes de p2x3 et p2x2/3 | |
DE60231868D1 (de) | Folat-mimetika und deren folatrezeptorbindende konjugate | |
MA30128B1 (fr) | Combinaisons pharmaceutiques d'un antagoniste de receptuer d'angiotensine et d'un inhibiteur de nep | |
IS7583A (is) | Kalsítóníngen-skyld peptíð viðtaka mótlyf | |
ATE490779T1 (de) | Y4-selektive rezeptoragonist für therapeutische interventionen | |
ATE525378T1 (de) | Himbacinanaloga als thrombinrezeptorantagonisten | |
FR2906808B1 (fr) | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers | |
ATE537864T1 (de) | Vibriervorrichtung zur behandlung von nasaler kongestion und sinusitis-symptomen | |
NO20070294L (no) | Gonadotropinfrigjorende hormon reseptor antagonister | |
MA28843B1 (fr) | Therapie d'association utilisant des proteines de fusion de trasferrine comprenant glp-1 | |
MA29080B1 (fr) | Derives de la quinuclidine et leur utilisation en tant qu'antagonistes du recepteur m3 muscarinique | |
MA28755B1 (fr) | Derives de pyrimidine fusionnes et compositions sur leur base, utilises en tant que modulateurs du recepteur de cxcr3, utiles dans la prevention et le traitement de maladies et troubles inflammatoires ou immunoregulateurs | |
TW200635919A (en) | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | |
MA28363A1 (fr) | Antagonistes des recepteurs muscariniques de l'acetylcholine | |
MA28359A1 (fr) | Antagonistes du recepteur a l'hydroisoindoline tachykinine | |
NO20082345L (no) | Selektive VPAC2 reseptorpeptidagonister | |
ATE457736T1 (de) | Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid | |
ATE389670T1 (de) | Selektive peptidische agonisten des vpac2- rezeptors | |
CA2530027A1 (fr) | Nouvelles matrices du recepteur de la melanocortine, nouveaux peptides et leur utilisation | |
MA29288B1 (fr) | Agonistes et antagonistes complets et partiels tres puissants du recepteur de la nociceptine/orphanine fq | |
MA28602B1 (fr) | Pyridin-4-yl-ethynyl-imidazoles et pyrazoles en tant qu'antagonistes des recepteurs mglur5 | |
MA30901B1 (fr) | Therapie de combinaison sequentielle | |
ATE519498T1 (de) | Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen | |
FR2894142B1 (fr) | Utilisation de l'association du dipeptide tyrosine-arginine et de la niacimanide en tant qu'antagoniste de substance p | |
DE602005010578D1 (de) | Selektive peptidische agonisten des vpac2-rezeptors |